Tag Archives: Orsiro

Desempeño de los DES actuales ¿hay margen para mejorar?

Current DES Performance: Is There Room for Improvement?

Current DES Performance: Is There Room for Improvement?

Head-to-head comparison of current drug-eluting stents (DES) showed contradictory results that led us to believe, for years, that we had reached a plateau. This feeling was also fostered by the disappointment caused by Absorb and bioresorbable-polymer stents. However, this recent article featured in JACC Interventions shows a light at the end of the tunnel with

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

More Evidence for Short Term DAPT: Approaching “the Class Effect”

Patients at high risk of bleeding undergoing coronary angioplasty with Orsiro stent can be considered for a short dual antiplatelet scheme.  These data come from the SMART-CHOICE study recently published in JAHA, adding the Orsiro stent to the list of devices supporting 3-month DAPT.  This study included 2993 patients undergoing coronary angioplasty randomized to 3

struts ultrafinos

BIOFLOW V: Ultrathin Struts Confirm their Benefits

For several years we have been testing new devices that have introduce changes with respect to their predecessors in the hope they will bring clinical benefits.  And so, the different generations of drug eluting stents came about (DES) even though we found ourselves stuck in the second generation, with the classical everolimus eluting stents. All

Top